ADMA Biologics Key Fundamental Indicators
| ADMA Stock | USD 16.09 0.50 3.21% |
As of the 17th of February 2026, ADMA Biologics shows the Risk Adjusted Performance of 0.0576, mean deviation of 2.14, and Semi Deviation of 2.36. ADMA Biologics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.
ADMA Biologics Total Revenue |
|
Gross Profit | Profit Margin | Market Capitalization | Enterprise Value Revenue 7.8826 | Revenue |
ADMA | Select Account or Indicator | Build AI portfolio with ADMA Stock |
ADMA Biologics Balance Sheet | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADMA Biologics Income Statement | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADMA Biologics Cash Flow Statement | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Ratios | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADMA Biologics Valuation Data | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADMA Fundamental Market Drivers
| Forward Price Earnings | 28.9855 | |
| Cash And Short Term Investments | 103.1 M |
ADMA Upcoming Events
| 28th of March 2024 Upcoming Quarterly Report | View | |
| 8th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 28th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
ADMA Current Valuation Driver Correlations
Understanding the fundamental principles of building solid financial models for ADMA Biologics is extremely important. It helps to project a fair market value of ADMA Stock properly, considering its historical fundamentals such as Current Valuation. Since ADMA Biologics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of ADMA Biologics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of ADMA Biologics' interrelated accounts and indicators.
Click cells to compare fundamentals
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ADMA Biologics. If investors know ADMA will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive ADMA Biologics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share 0.86 | Revenue Per Share | Quarterly Revenue Growth 0.12 | Return On Assets | Return On Equity |
ADMA Biologics's market price often diverges from its book value, the accounting figure shown on ADMA's balance sheet. Smart investors calculate ADMA Biologics' intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Since ADMA Biologics' trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Understanding that ADMA Biologics' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether ADMA Biologics represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. However, ADMA Biologics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
ADMA Biologics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to ADMA Biologics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of ADMA Biologics.
| 11/19/2025 |
| 02/17/2026 |
If you would invest 0.00 in ADMA Biologics on November 19, 2025 and sell it all today you would earn a total of 0.00 from holding ADMA Biologics or generate 0.0% return on investment in ADMA Biologics over 90 days. ADMA Biologics is related to or competes with ACADIA Pharmaceuticals, Praxis Precision, Belite Bio, Ligand Pharmaceuticals, Soleno Therapeutics, Mirum Pharmaceuticals, and Dyne Therapeutics. ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-... More
ADMA Biologics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure ADMA Biologics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess ADMA Biologics upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 2.51 | |||
| Information Ratio | 0.0374 | |||
| Maximum Drawdown | 14.85 | |||
| Value At Risk | (4.24) | |||
| Potential Upside | 4.86 |
ADMA Biologics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for ADMA Biologics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as ADMA Biologics' standard deviation. In reality, there are many statistical measures that can use ADMA Biologics historical prices to predict the future ADMA Biologics' volatility.| Risk Adjusted Performance | 0.0576 | |||
| Jensen Alpha | 0.0851 | |||
| Total Risk Alpha | (0.04) | |||
| Sortino Ratio | 0.0412 | |||
| Treynor Ratio | 0.1251 |
ADMA Biologics February 17, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0576 | |||
| Market Risk Adjusted Performance | 0.1351 | |||
| Mean Deviation | 2.14 | |||
| Semi Deviation | 2.36 | |||
| Downside Deviation | 2.51 | |||
| Coefficient Of Variation | 1597.84 | |||
| Standard Deviation | 2.77 | |||
| Variance | 7.68 | |||
| Information Ratio | 0.0374 | |||
| Jensen Alpha | 0.0851 | |||
| Total Risk Alpha | (0.04) | |||
| Sortino Ratio | 0.0412 | |||
| Treynor Ratio | 0.1251 | |||
| Maximum Drawdown | 14.85 | |||
| Value At Risk | (4.24) | |||
| Potential Upside | 4.86 | |||
| Downside Variance | 6.31 | |||
| Semi Variance | 5.59 | |||
| Expected Short fall | (2.45) | |||
| Skewness | 0.4309 | |||
| Kurtosis | 0.7679 |
ADMA Biologics Backtested Returns
At this point, ADMA Biologics is not too volatile. ADMA Biologics secures Sharpe Ratio (or Efficiency) of 0.0182, which signifies that the company had a 0.0182 % return per unit of return volatility over the last 3 months. We have found twenty-nine technical indicators for ADMA Biologics, which you can use to evaluate the volatility of the firm. Please confirm ADMA Biologics' Mean Deviation of 2.14, risk adjusted performance of 0.0576, and Semi Deviation of 2.36 to double-check if the risk estimate we provide is consistent with the expected return of 0.0466%. ADMA Biologics has a performance score of 1 on a scale of 0 to 100. The firm shows a Beta (market volatility) of 1.31, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, ADMA Biologics will likely underperform. ADMA Biologics at this time shows a risk of 2.55%. Please confirm ADMA Biologics standard deviation, treynor ratio, downside variance, as well as the relationship between the total risk alpha and value at risk , to decide if ADMA Biologics will be following its price patterns.
Auto-correlation | -0.38 |
Poor reverse predictability
ADMA Biologics has poor reverse predictability. Overlapping area represents the amount of predictability between ADMA Biologics time series from 19th of November 2025 to 3rd of January 2026 and 3rd of January 2026 to 17th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of ADMA Biologics price movement. The serial correlation of -0.38 indicates that just about 38.0% of current ADMA Biologics price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.38 | |
| Spearman Rank Test | -0.03 | |
| Residual Average | 0.0 | |
| Price Variance | 0.66 |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, ADMA Biologics has a Current Valuation of 3.85 B. This is 73.19% lower than that of the Biotechnology sector and 17.1% lower than that of the Health Care industry. The current valuation for all United States stocks is 76.83% higher than that of the company.
ADMA Biologics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining ADMA Biologics's current stock value. Our valuation model uses many indicators to compare ADMA Biologics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across ADMA Biologics competition to find correlations between indicators driving ADMA Biologics's intrinsic value. More Info.ADMA Biologics is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers reporting about 0.34 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for ADMA Biologics is roughly 2.90 . At present, ADMA Biologics' Return On Equity is projected to slightly grow based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the ADMA Biologics' earnings, one of the primary drivers of an investment's value.ADMA Biologics' Earnings Breakdown by Geography
ADMA Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses ADMA Biologics' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of ADMA Biologics could also be used in its relative valuation, which is a method of valuing ADMA Biologics by comparing valuation metrics of similar companies.ADMA Biologics is currently under evaluation in current valuation category among its peers.
ADMA Biologics Current Valuation Drivers
We derive many important indicators used in calculating different scores of ADMA Biologics from analyzing ADMA Biologics' financial statements. These drivers represent accounts that assess ADMA Biologics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of ADMA Biologics' important valuation drivers and their relationship over time.
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Market Cap | 196.8M | 767.8M | 1.0B | 4.0B | 3.6B | 3.8B | |
| Enterprise Value | 248.6M | 835.7M | 1.1B | 4.0B | 3.6B | 3.8B |
ADMA Biologics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, ADMA Biologics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to ADMA Biologics' managers, analysts, and investors.Environmental | Governance | Social |
ADMA Fundamentals
| Return On Equity | 0.63 | ||||
| Return On Asset | 0.22 | ||||
| Profit Margin | 0.43 % | ||||
| Operating Margin | 0.38 % | ||||
| Current Valuation | 3.85 B | ||||
| Shares Outstanding | 238 M | ||||
| Shares Owned By Insiders | 2.74 % | ||||
| Shares Owned By Institutions | 95.94 % | ||||
| Number Of Shares Shorted | 19.44 M | ||||
| Price To Earning | (1.55) X | ||||
| Price To Book | 8.88 X | ||||
| Price To Sales | 7.86 X | ||||
| Revenue | 426.45 M | ||||
| Gross Profit | 267.28 M | ||||
| EBITDA | 147.69 M | ||||
| Net Income | 197.67 M | ||||
| Cash And Equivalents | 52.42 M | ||||
| Cash Per Share | 0.27 X | ||||
| Total Debt | 82.12 M | ||||
| Debt To Equity | 1.32 % | ||||
| Current Ratio | 7.94 X | ||||
| Book Value Per Share | 1.81 X | ||||
| Cash Flow From Operations | 118.67 M | ||||
| Short Ratio | 8.33 X | ||||
| Earnings Per Share | 0.86 X | ||||
| Target Price | 25.67 | ||||
| Number Of Employees | 677 | ||||
| Beta | 0.48 | ||||
| Market Capitalization | 3.84 B | ||||
| Total Asset | 488.68 M | ||||
| Retained Earnings | (308.58 M) | ||||
| Working Capital | 275.87 M | ||||
| Current Asset | 21.29 M | ||||
| Current Liabilities | 4.22 M | ||||
| Net Asset | 488.68 M |
About ADMA Biologics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze ADMA Biologics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ADMA Biologics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ADMA Biologics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 164.4 K | 148.8 K | |
| Total Revenue | 490.4 M | 514.9 M | |
| Cost Of Revenue | 237.9 M | 249.8 M | |
| Stock Based Compensation To Revenue | 0.04 | 0.03 | |
| Sales General And Administrative To Revenue | 1.52 | 1.40 | |
| Capex To Revenue | 0.02 | 0.02 | |
| Revenue Per Share | 1.65 | 1.73 | |
| Ebit Per Revenue | 0.29 | 0.31 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether ADMA Biologics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of ADMA Biologics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Adma Biologics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Adma Biologics Stock:Check out For information on how to trade ADMA Stock refer to our How to Trade ADMA Stock guide.You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ADMA Biologics. If investors know ADMA will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive ADMA Biologics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share 0.86 | Revenue Per Share | Quarterly Revenue Growth 0.12 | Return On Assets | Return On Equity |
ADMA Biologics's market price often diverges from its book value, the accounting figure shown on ADMA's balance sheet. Smart investors calculate ADMA Biologics' intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Since ADMA Biologics' trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Understanding that ADMA Biologics' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether ADMA Biologics represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. However, ADMA Biologics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.